熊去氧胆酸治疗原发性胆汁性肝硬化的临床观察

The Clinical Observation on Ursodesoxycholic Acid in the Treatment of Primary Biliary Cirrhosis

目的探讨采用熊去氧胆酸对原发性胆汁性肝硬化进行治疗的临床效果。方法选择本院住院及门诊诊治的原发性胆汁性肝硬化患者86例,将其随机分为观察组和对照组,各43例。两组患者均给予保肝及支持治疗,对照组予以口服泼尼松龙,观察组给予以口服熊去氧胆酸。两组患者均治疗4周为1个疗程。结果两组临床治疗总有效率明显高于对照组,差异有统计学意义(P<0.05)。结论熊去氧胆酸治疗原发性胆汁性肝硬化临床疗效显著,能更好改善患者临床症状,及肝功能异常指标,并具有良好的安全性。

Objective To discuss the clinical effect of primary biliary cirrhosis treated by ursodesoxycholic acid. Methods To selected 86 cases patients with primary biliary cirrhosis in outpatient clinic at our hospital, to randomly divided into the treatment group and the control group, each group had 43 cases. The patients were given the liver protection and supportive treatment, the control group was given the prednisolone by oral, and the treatment group was given the ursodesoxycholic acid by oral. They were treated for 4 weeks as one course of treatment. Results The total effective rate of clinical treatment of the treatment group was significantly greater than the control group, there was statistical significance（P〈0.05）. Conclusion That has the significantly clinical effect of primary biliary cirrhosis treated by ursodesoxycholic acid, and preferable improve the clinical symptoms and anomaly index of liver function, that has the favourable security.